Cite
Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC).
MLA
Morland, Bruce, et al. “Plerixafor Combined with Standard Regimens for Hematopoietic Stem Cell Mobilization in Pediatric Patients with Solid Tumors Eligible for Autologous Transplants: Two-Arm Phase I/II Study (MOZAIC).” Bone Marrow Transplantation, vol. 55, no. 9, Sept. 2020, pp. 1744–53. EBSCOhost, https://doi.org/10.1038/s41409-020-0836-2.
APA
Morland, B., Kepak, T., Dallorso, S., Sevilla, J., Murphy, D., Luksch, R., Yaniv, I., Bader, P., Rößler, J., Bisogno, G., Maecker-Kolhoff, B., Lang, P., Zwaan, C. M., Sumerauer, D., Kriván, G., Bernard, J., Liu, Q., Doyle, E., & Locatelli, F. (2020). Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC). Bone Marrow Transplantation, 55(9), 1744–1753. https://doi.org/10.1038/s41409-020-0836-2
Chicago
Morland, Bruce, Tomas Kepak, Sandro Dallorso, Julian Sevilla, Dermot Murphy, Roberto Luksch, Isaac Yaniv, et al. 2020. “Plerixafor Combined with Standard Regimens for Hematopoietic Stem Cell Mobilization in Pediatric Patients with Solid Tumors Eligible for Autologous Transplants: Two-Arm Phase I/II Study (MOZAIC).” Bone Marrow Transplantation 55 (9): 1744–53. doi:10.1038/s41409-020-0836-2.